A Phase 1 interventional study of CKD-383(Fed) and CKD-383(Fasted) in Type 2 Diabetes Mellitus, sponsored by Chong Kun Dang Pharmaceutical. Not yet recruiting. Open to participants aged 19 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-10.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Chong Kun Dang Pharmaceutical.
Among the 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical, this one is the 37th largest by planned enrollment of the 62 interventional ones that give a count, is one of 8 that started in 2024, is one of 53 in phase 1, and was the 56th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical are open now, in 1 country. Recruiting first, the newest first:
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 19 Years to 54 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 30 across the 62 interventional studies, 6,114 across the 2 observational. Of the 45 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
1 of the studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07365358Chong Kun Dang PharmaceuticalEvaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, single dose, crossover, phase 1 trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-383 in healthy volunteers
Participants were randomly assigned in a 1:1 ratio. TheParticipants are prescribed oral administration of the appropriate IP(2 tablets in single dose: actual medication)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
who has taken drug metabolism enzyme induction and inhibitory drugs, such as barbitale drugs, within 30 days prior to the start of the trial (Period
1 administration)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Period 1: CKD-383 two tablets(Fed) * Period 2: CKD-383 two tablets(Fasted)
Drug: CKD-383(Fed) · Drug: CKD-383(Fasted)
* Period 1: CKD-383 two tablets(Fasted) * Period 2: CKD-383 two tablets(Fed)
Drug: CKD-383(Fed) · Drug: CKD-383(Fasted)
After maintaining NPO for at least 10 hours before a high-fat meal, take a high-fat meal within 20 minutes on each medication day, and take CKD-383 two tablets orally with 150 mL of water at room temperature.
Also known as: Lobeglitazone, Empagliflozin, Metformin
After maintaining NPO for at least 10 hours before dosing, and take CKD-383 two tablets orally with 150 mL of room temperature water with 30g of sugar added on each dosing day.
Also known as: Lobeglitazone, Empagliflozin, Metformin
AUCt of Empagliflozin, sitagliptin, metformin(Participants greater than or equal to 18.0 kg/m2 and less than 30 kg/m2)
Pharmacokinetic characterization
Time frame: 0 hour ~ 48 hour after drug administration
Cmax of Empagliflozin, sitagliptin, metformin(Participants greater than or equal to 18.0 kg/m2 and less than 30 kg/m2)
Pharmacokinetic characterization
Time frame: 0 hour ~ 48 hour after drug administration
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2024; primary completion for Aug 2024, 0 months later.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 0 months is below that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chong Kun Dang Pharmaceutical →